Xiangyi Meng
Xiangyi Meng has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Brandon Brown
Novartis Pharmaceuticals Corporation East Hanover NJ United States
2 shared publications- George Thomas Grossberg
Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine
2 shared publications - Gustavo Alva
ATP Clinical Research, Costa Mesa, CA, USA
2 shared publications Adriana Guana
Novartis Pharmaceuticals Corporation, East Hanover, USA
1 shared publication- Alexis Ogdie
Perelman School of Medicine University of Pennsylvania Philadelphia
1 shared publication - Barry A. Singer
The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA
1 shared publication
Latest Publications
- Open Access
- 23 April 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (Supplement)
P266 Secukinumab provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of five phase 3 studies
Evidence for the efficacy of biologics in patients with oligoarticular psoriatic arthritis (PsA) is limited. We evaluated the efficacy of the interleukin 17 inhibitor secukinumab in patients with oligoarticular PsA pooled from 5 phase 3 studies. This post hoc analysis included patients with oligoarticular PsA from the FUTURE 2-5 and MAXIMISE trials (NCT01649375, NCT01989468, NCT02294227, NCT02404350, and NCT02721966). Oligoarticular PsA was defined as the presence of 1-4 tender joints and 1-4 swollen joints at baseline as measured by the tender joint count of 78 joints (TJC78) and the swollen joint count of 76 joints (SJC76), respectively. Patients were pooled by treatment received at week 12 and week 52 in the following groups: week 12 (secukinumab 300 mg, secukinumab 150 mg with or without loading dose [LD], or placebo) and week 52 (any secukinumab 300 mg or any secukinumab 150 mg). Efficacy was assessed by the proportion of patients achieving 50% improvement in Disease Activity in Psoriatic Arthritis (DAPSA50), DAPSA75, DAPSA-based low disease activity (LDA; DAPSA ≤14) and remission (REM; DAPSA ≤4), resolution of TJC78, resolution of SJC76, and a ≥ 0.35-point improvement in the Health Assessment Questionnaire-Disability Index score. Descriptive statistics are provided for each endpoint. Logistic regression analysis was used to identify potential predictors of DAPSA response at weeks 12 and 52; multivariate logistic regression analyses were performed thereafter. 84 patients were included: 48 with active PsA from the FUTURE 2-5 trials and 36 with active PsA and axial manifestations from the MAXIMISE trial. Demographics and baseline disease characteristics were comparable across groups. At week 12, notable improvements were observed for the secukinumab 300 and 150 mg versus placebo groups across all the assessed outcome measures and were sustained or increased through week 52. More than 78% of patients who received secukinumab 300 mg or secukinumab 150 mg achieved LDA or REM at week 12. More than 90% of patients who received any secukinumab 300 mg or secukinumab 150 mg achieved LDA or REM at week 52. At week 52, a higher proportion of patients who received any secukinumab 300 mg versus any secukinumab 150 mg achieved higher hurdle endpoints of DAPSA75 (58.1% versus 43.6%, respectively) and DAPSA REM (61.3% versus 37.5%, respectively). At week 12, younger age was a predictor for the achievement of DAPSA LDA or REM and the achievement of DAPSA50, while lower baseline SJC was a predictor of the achievement of DAPSA REM (P < 0.05). No predictors were identified at week 52. Secukinumab provides greater improvements versus placebo across a number of disease activity and physical function outcome measures in patients with oligoarticular PsA at week 12, with sustained responses through week 52. L.C. Coates: Honoraria; AbbVie, Amgen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, UCB. Grants/research support; AbbVie, Celgene, Eli Lilly, Novartis, Pfizer. A. Ogdie: Consultancies; Amgen, AbbVie, BMS, Celgene, Novartis, Lilly, Janssen, Gilead, Pfizer, UCB. Grants/research support; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Amgen, Pfizer, Novartis. D.D. Gladman: Consultancies; AbbVie, Amgen, Bristol Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, UCB. Grants/research support; AbbVie, Amgen, Celgene, Eli Lilly, Novartis, Pfizer, UCB. E. Pournara: Shareholder/stock ownership; Novartis. Other; Employee of Novartis. X. Meng: Other; Employee of Novartis. B. Parikh: Other; Employee of Novartis. P.J. Mease: Consultancies; AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, UCB. Member of speakers’ bureau; AbbVie, Amgen, Janssen, Eli Lilly, Novartis, Pfizer, UCB. Grants/research support; AbbVie, Amgen, Bristol Myers Squibb, Celgene, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, UCB.
- 23 April 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (Supplement)
Open AccessP266 Secukinumab provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of five phase 3 studies
Evidence for the efficacy of biologics in patients with oligoarticular psoriatic arthritis (PsA) is limited. We evaluated the efficacy of the interleukin 17 inhibitor secukinumab in patients with oligoarticular PsA pooled from 5 phase 3 studies. This post hoc analysis included patients with oligoarticular PsA from the FUTURE 2-5 and MAXIMISE trials (NCT01649375, NCT01989468, NCT02294227, NCT02404350, and NCT02721966). Oligoarticular PsA was defined as the presence of 1-4 tender joints and 1-4 swollen joints at baseline as measured by the tender joint count of 78 joints (TJC78) and the swollen joint count of 76 joints (SJC76), respectively. Patients were pooled by treatment received at week 12 and week 52 in the following groups: week 12 (secukinumab 300 mg, secukinumab 150 mg with or without loading dose [LD], or placebo) and week 52 (any secukinumab 300 mg or any secukinumab 150 mg). Efficacy was assessed by the proportion of patients achieving 50% improvement in Disease Activity in Psoriatic Arthritis (DAPSA50), DAPSA75, DAPSA-based low disease activity (LDA; DAPSA ≤14) and remission (REM; DAPSA ≤4), resolution of TJC78, resolution of SJC76, and a ≥ 0.35-point improvement in the Health Assessment Questionnaire-Disability Index score. Descriptive statistics are provided for each endpoint. Logistic regression analysis was used to identify potential predictors of DAPSA response at weeks 12 and 52; multivariate logistic regression analyses were performed thereafter. 84 patients were included: 48 with active PsA from the FUTURE 2-5 trials and 36 with active PsA and axial manifestations from the MAXIMISE trial. Demographics and baseline disease characteristics were comparable across groups. At week 12, notable improvements were observed for the secukinumab 300 and 150 mg versus placebo groups across all the assessed outcome measures and were sustained or increased through week 52. More than 78% of patients who received secukinumab 300 mg or secukinumab 150 mg achieved LDA or REM at week 12. More than 90% of patients who received any secukinumab 300 mg or secukinumab 150 mg achieved LDA or REM at week 52. At week 52, a higher proportion of patients who received any secukinumab 300 mg versus any secukinumab 150 mg achieved higher hurdle endpoints of DAPSA75 (58.1% versus 43.6%, respectively) and DAPSA REM (61.3% versus 37.5%, respectively). At week 12, younger age was a predictor for the achievement of DAPSA LDA or REM and the achievement of DAPSA50, while lower baseline SJC was a predictor of the achievement of DAPSA REM (P < 0.05). No predictors were identified at week 52. Secukinumab provides greater improvements versus placebo across a number of disease activity and physical function outcome measures in patients with oligoarticular PsA at week 12, with sustained responses through week 52. L.C. Coates: Honoraria; AbbVie, Amgen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, UCB. Grants/research support; AbbVie, Celgene, Eli Lilly, Novartis, Pfizer. A. Ogdie: Consultancies; Amgen, AbbVie, BMS, Celgene, Novartis, Lilly, Janssen, Gilead, Pfizer, UCB. Grants/research support; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Amgen, Pfizer, Novartis. D.D. Gladman: Consultancies; AbbVie, Amgen, Bristol Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, UCB. Grants/research support; AbbVie, Amgen, Celgene, Eli Lilly, Novartis, Pfizer, UCB. E. Pournara: Shareholder/stock ownership; Novartis. Other; Employee of Novartis. X. Meng: Other; Employee of Novartis. B. Parikh: Other; Employee of Novartis. P.J. Mease: Consultancies; AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, UCB. Member of speakers’ bureau; AbbVie, Amgen, Janssen, Eli Lilly, Novartis, Pfizer, UCB. Grants/research support; AbbVie, Amgen, Bristol Myers Squibb, Celgene, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, UCB.
- Open Access
- 1 August 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (8) , 1095-1104
24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%
- 1 August 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (8) , 1095-1104
Open Access24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%
- 24 June 2019
- Published by Wiley in The Manchester School
- Vol. 87 (6) , 875-889
Helping‐Hand Corruption, Bribery Contests and Private‐Side Caused Persistent Corruption
This paper describes contests in which private agents bribe local government officials to give them a ‘helping hand’ through government policy. The model is similar to a rent‐seeking contest but bribes are transfers of income to government officials. The officials differ in ethics regarding their willingness to accept bribes. If the ethics of officials are known, the officials lose income from bribes because of their honesty. Other corrupt officials gain from the presence of honest officials. We show that bribery contests could generate long‐run equilibria where corruption is persistent. There are multiple long‐run equilibria and the specific one where the economy converges depends on the initial level of corruption. Furthermore, the equilibria that exist in the model can be Pareto ranked from the perspective of the bribers: the equilibrium without corruption is always Pareto efficient. We also show that for the government services/goods with the same value, a larger number of applicants leads to a higher equilibrium level of corruption.
- 24 June 2019
- Published by Wiley in The Manchester School
- Vol. 87 (6) , 875-889
Helping‐Hand Corruption, Bribery Contests and Private‐Side Caused Persistent Corruption
This paper describes contests in which private agents bribe local government officials to give them a ‘helping hand’ through government policy. The model is similar to a rent‐seeking contest but bribes are transfers of income to government officials. The officials differ in ethics regarding their willingness to accept bribes. If the ethics of officials are known, the officials lose income from bribes because of their honesty. Other corrupt officials gain from the presence of honest officials. We show that bribery contests could generate long‐run equilibria where corruption is persistent. There are multiple long‐run equilibria and the specific one where the economy converges depends on the initial level of corruption. Furthermore, the equilibria that exist in the model can be Pareto ranked from the perspective of the bribers: the equilibrium without corruption is always Pareto efficient. We also show that for the government services/goods with the same value, a larger number of applicants leads to a higher equilibrium level of corruption.
- Open Access
- 10 April 2017
- Published by Springer Nature in Advances in Therapy
- Vol. 34 (6) , 1327-1339
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Introduction There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients. Methods Data were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup. Results Efficacy responses (Psoriasis Area and Severity Index [PASI] 75/90/100 and Investigator’s Global Assessment 2011 modified version 0/1) for secukinumab 300 mg were greater than for etanercept at week 12 in the Hispanic and non-Hispanic patient subgroups. At week 12 with secukinumab 300 mg, PASI 90/100 responses were achieved by 70.6%/35.9% of Hispanic patients and 58.0%/28.1% of non-Hispanic patients. At week 12 with secukinumab 150 mg, PASI 90/100 responses were achieved by 59.5%/25.1% of Hispanic patients and 41.2%/13.4% of non-Hispanic patients. In both subgroups, peak efficacy responses with secukinumab were observed at week 16 and were maintained to week 52. Conclusions Secukinumab is highly effective for clearing psoriasis in both Hispanic and non-Hispanic patients. Funding Novartis Pharmaceutical Corporation.
- 10 April 2017
- Published by Springer Nature in Advances in Therapy
- Vol. 34 (6) , 1327-1339
Open AccessSecukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Introduction There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients. Methods Data were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup. Results Efficacy responses (Psoriasis Area and Severity Index [PASI] 75/90/100 and Investigator’s Global Assessment 2011 modified version 0/1) for secukinumab 300 mg were greater than for etanercept at week 12 in the Hispanic and non-Hispanic patient subgroups. At week 12 with secukinumab 300 mg, PASI 90/100 responses were achieved by 70.6%/35.9% of Hispanic patients and 58.0%/28.1% of non-Hispanic patients. At week 12 with secukinumab 150 mg, PASI 90/100 responses were achieved by 59.5%/25.1% of Hispanic patients and 41.2%/13.4% of non-Hispanic patients. In both subgroups, peak efficacy responses with secukinumab were observed at week 16 and were maintained to week 52. Conclusions Secukinumab is highly effective for clearing psoriasis in both Hispanic and non-Hispanic patients. Funding Novartis Pharmaceutical Corporation.
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Estimation of Brain Volume Loss with Multiple Imputation of Missing Values in the Placebo-Controlled FREEDOMS Trials of Fingolimod (P3.056)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Estimation of Brain Volume Loss with Multiple Imputation of Missing Values in the Placebo-Controlled FREEDOMS Trials of Fingolimod (P3.056)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
First-Dose Effects of Fingolimod in Patients with RRMS Receiving Concomitant SSRIs on Day 1: Pooled Analysis of the Real-World PREFERMS and EPOC Studies (P2.090)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
First-Dose Effects of Fingolimod in Patients with RRMS Receiving Concomitant SSRIs on Day 1: Pooled Analysis of the Real-World PREFERMS and EPOC Studies (P2.090)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Early Clinical Efficacy of Fingolimod Compared with Interferon Beta-1a in Relapsing Multiple Sclerosis (P6.169)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Early Clinical Efficacy of Fingolimod Compared with Interferon Beta-1a in Relapsing Multiple Sclerosis (P6.169)
- 18 February 2014
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 29 (9) , 920-927
Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis
Objective Rivastigmine displays dose‐dependent efficacy on cognition in patients with Alzheimer's disease (AD), as measured by the Alzheimer's Disease Assessment Scale–cognitive subscale (ADAS‐cog). Subanalysis of the OPTIMA (OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease) study aimed to define ADAS‐cog domains by factor analysis of individual items. Efficacy of 13.3 mg/24 h versus 9.5 mg/24 h rivastigmine patch on individual items and newly derived domains was assessed. Methods OPTIMA was a 48‐week, double‐blind (DB) study in patients with mild‐to‐moderate AD. Patients meeting pre‐defined decline criteria during open‐label treatment with 9.5 mg/24 h patch were randomized in the DB phase to 13.3 mg/24 h (n = 280) or 9.5 mg/24 h (n = 287) patch. ADAS‐cog change from baseline was a co‐primary outcome measure. Factor analysis categorized ADAS‐cog items into newly derived domains. Change from DB‐baseline was calculated for domains and individual items. Results Numerically, less decline was displayed with 13.3 mg/24 h versus 9.5 mg/24 h patch in the total ADAS‐cog score at all time points (significant at Week 24, p = 0.027). Factor analysis identified two domains: memory and language. Significantly, less decline was observed on the memory domain with 13.3 mg/24 h versus 9.5 mg/24 h patch at Weeks 12, 24, and 48 (p < 0.05; observed cases). Three items (following commands, orientation, and word recognition) displayed numerically less decline with 13.3 mg/24 h versus 9.5 mg/24 h patch at all time points. No significant between‐group differences were observed on the language domain. Conclusion Results suggest that the greater cognitive efficacy of 13.3 mg/24 h versus 9.5 mg/24 h rivastigmine patch is driven primarily by effects on memory, particularly in the areas of following commands, orientation, and word recognition. Copyright © 2014 John Wiley & Sons, Ltd.
- 18 February 2014
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 29 (9) , 920-927
Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis
Objective Rivastigmine displays dose‐dependent efficacy on cognition in patients with Alzheimer's disease (AD), as measured by the Alzheimer's Disease Assessment Scale–cognitive subscale (ADAS‐cog). Subanalysis of the OPTIMA (OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease) study aimed to define ADAS‐cog domains by factor analysis of individual items. Efficacy of 13.3 mg/24 h versus 9.5 mg/24 h rivastigmine patch on individual items and newly derived domains was assessed. Methods OPTIMA was a 48‐week, double‐blind (DB) study in patients with mild‐to‐moderate AD. Patients meeting pre‐defined decline criteria during open‐label treatment with 9.5 mg/24 h patch were randomized in the DB phase to 13.3 mg/24 h (n = 280) or 9.5 mg/24 h (n = 287) patch. ADAS‐cog change from baseline was a co‐primary outcome measure. Factor analysis categorized ADAS‐cog items into newly derived domains. Change from DB‐baseline was calculated for domains and individual items. Results Numerically, less decline was displayed with 13.3 mg/24 h versus 9.5 mg/24 h patch in the total ADAS‐cog score at all time points (significant at Week 24, p = 0.027). Factor analysis identified two domains: memory and language. Significantly, less decline was observed on the memory domain with 13.3 mg/24 h versus 9.5 mg/24 h patch at Weeks 12, 24, and 48 (p < 0.05; observed cases). Three items (following commands, orientation, and word recognition) displayed numerically less decline with 13.3 mg/24 h versus 9.5 mg/24 h patch at all time points. No significant between‐group differences were observed on the language domain. Conclusion Results suggest that the greater cognitive efficacy of 13.3 mg/24 h versus 9.5 mg/24 h rivastigmine patch is driven primarily by effects on memory, particularly in the areas of following commands, orientation, and word recognition. Copyright © 2014 John Wiley & Sons, Ltd.
- 7 December 2011
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 27 (1) , 24-32
Efficacy of iloperidone in the short‐term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo‐ and active‐controlled trials
Objectives: The efficacy and tolerability characteristics of an antipsychotic are difficult to determine from a single registration study. We thus conducted an analysis that assessed key efficacy and tolerability outcomes post hoc from four pooled short‐term (4–6 weeks) phase III studies that evaluated iloperidone versus placebo in patients with schizophrenia or schizoaffective disorder.Methods: Patient‐level data were pooled from four prospective, randomized, double‐blind, placebo‐controlled and active‐controlled, multicenter trials of iloperidone in patients with schizophrenia or schizoaffective disorder aged 18–65 years. Iloperidone 4–8, 10–16, and 20–24 mg/day (all dosed twice daily) were compared with placebo. Active controls used for assay sensitivity included risperidone 4–8 mg/day, haloperidol 15 mg/day, and ziprasidone 160 mg/day. Outcomes of interest were change from baseline to endpoint in the Brief Psychiatric Rating Scale (derived) (BPRSd), Positive and Negative Syndrome Scale (PANSS)‐total (PANSS‐T) score, and PANSS‐positive (PANSS‐P) and PANSS‐negative (PANSS‐N) subscale scores. An analysis of covariance (with treatment and study as factors, baseline as a covariate) was performed to compare changes between the iloperidone treatment groups versus placebo, on the basis of a last‐observation‐carried‐forward approach for the intent‐to‐treat (ITT) populations. Tolerability outcomes were obtained from spontaneously reported adverse events (AEs), and number needed to harm was calculated for each antipsychotic versus placebo for the total population.Results: The ITT population included both schizoaffective and schizophrenia patients (N = 2401): n = 370, n = 494, and n = 424 for iloperidone 4–8, 10–16, and 20–24 mg/day, respectively; n = 294 for risperidone; n = 114 for haloperidol; n = 144 for ziprasidone; and n = 561 for placebo. Treatment with iloperidone 10–16 mg/day or 20–24 mg/day was associated with significantly improved BPRSd, PANSS‐T, PANSS‐P, and PANSS‐N scores versus treatment with placebo. When only patients with schizophrenia were included (n = 1941), the pattern of results was essentially unchanged. The active controls confirmed assay sensitivity. Across all iloperidone dose groups, the incidences of extrapyramidal disorders and akathisia were similar to those observed with placebo. AEs for which the frequency was greater for iloperidone than placebo and for which the 95% confidence interval for number needed to harm did not contain infinity were dizziness, dry mouth, somnolence, nasal congestion, fatigue, sedation, and tachycardia; in general, for these AEs, frequency was higher with higher doses, resulting in a lower number needed to harm.Conclusions: Consistent with product labeling, iloperidone 10–16 mg/day or 20–24 mg/day demonstrated significant improvement over placebo on BPRSd and PANSS‐T scores, as well as on PANSS‐P and PANSS‐N subscale scores over 6 weeks of treatment in patients with schizophrenia and in the ITT population, which includes patients with schizoaffective disorder. Iloperidone did not differ from placebo in terms of extrapyramidal disorders and akathisia. Copyright © 2011 John Wiley & Sons, Ltd.
- 7 December 2011
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 27 (1) , 24-32
Efficacy of iloperidone in the short‐term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo‐ and active‐controlled trials
Objectives: The efficacy and tolerability characteristics of an antipsychotic are difficult to determine from a single registration study. We thus conducted an analysis that assessed key efficacy and tolerability outcomes post hoc from four pooled short‐term (4–6 weeks) phase III studies that evaluated iloperidone versus placebo in patients with schizophrenia or schizoaffective disorder.Methods: Patient‐level data were pooled from four prospective, randomized, double‐blind, placebo‐controlled and active‐controlled, multicenter trials of iloperidone in patients with schizophrenia or schizoaffective disorder aged 18–65 years. Iloperidone 4–8, 10–16, and 20–24 mg/day (all dosed twice daily) were compared with placebo. Active controls used for assay sensitivity included risperidone 4–8 mg/day, haloperidol 15 mg/day, and ziprasidone 160 mg/day. Outcomes of interest were change from baseline to endpoint in the Brief Psychiatric Rating Scale (derived) (BPRSd), Positive and Negative Syndrome Scale (PANSS)‐total (PANSS‐T) score, and PANSS‐positive (PANSS‐P) and PANSS‐negative (PANSS‐N) subscale scores. An analysis of covariance (with treatment and study as factors, baseline as a covariate) was performed to compare changes between the iloperidone treatment groups versus placebo, on the basis of a last‐observation‐carried‐forward approach for the intent‐to‐treat (ITT) populations. Tolerability outcomes were obtained from spontaneously reported adverse events (AEs), and number needed to harm was calculated for each antipsychotic versus placebo for the total population.Results: The ITT population included both schizoaffective and schizophrenia patients (N = 2401): n = 370, n = 494, and n = 424 for iloperidone 4–8, 10–16, and 20–24 mg/day, respectively; n = 294 for risperidone; n = 114 for haloperidol; n = 144 for ziprasidone; and n = 561 for placebo. Treatment with iloperidone 10–16 mg/day or 20–24 mg/day was associated with significantly improved BPRSd, PANSS‐T, PANSS‐P, and PANSS‐N scores versus treatment with placebo. When only patients with schizophrenia were included (n = 1941), the pattern of results was essentially unchanged. The active controls confirmed assay sensitivity. Across all iloperidone dose groups, the incidences of extrapyramidal disorders and akathisia were similar to those observed with placebo. AEs for which the frequency was greater for iloperidone than placebo and for which the 95% confidence interval for number needed to harm did not contain infinity were dizziness, dry mouth, somnolence, nasal congestion, fatigue, sedation, and tachycardia; in general, for these AEs, frequency was higher with higher doses, resulting in a lower number needed to harm.Conclusions: Consistent with product labeling, iloperidone 10–16 mg/day or 20–24 mg/day demonstrated significant improvement over placebo on BPRSd and PANSS‐T scores, as well as on PANSS‐P and PANSS‐N subscale scores over 6 weeks of treatment in patients with schizophrenia and in the ITT population, which includes patients with schizoaffective disorder. Iloperidone did not differ from placebo in terms of extrapyramidal disorders and akathisia. Copyright © 2011 John Wiley & Sons, Ltd.
- 15 March 2011
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 26 (4) , 356-363
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses
Objective In Alzheimer's disease (AD), rivastigmine has demonstrated statistically significant efficacy versus placebo on cognition and activities of daily living (ADL). The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items. Methods This exploratory analysis focused on the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS‐ADL) outcome from a large, international, 24‐week, controlled trial of rivastigmine once‐daily transdermal patch and twice‐daily capsules in AD (CENA713D2320, NCT00099242). Percentages of patients “improving” or “not worsening” on individual ADL items were calculated and changes from baseline with rivastigmine versus placebo were evaluated. Results Patients received rivastigmine patch (9.5 mg/24 h; n = 247), capsule (12 mg/day; n = 254), and placebo (n = 281). Statistically significant changes from baseline in composite ADCS‐ADL scores in both rivastigmine treatment groups versus placebo (p < 0.05) had previously been reported. In this responder analysis of the subset of patients who showed baseline functional impairments on each item, statistically significant differences favoring rivastigmine were seen on the following functions: bathing, clearing dishes, obtaining a beverage, garbage disposal, traveling, shopping, writing, using household appliances, and talking about current events. A responder analysis of emergence of ADL impairment was not as sensitive to treatment effects. Conclusions These findings suggest that rivastigmine may benefit specific ADL, particularly in patients who are already exhibiting functional impairment. Further research is required to improve understanding of how drugs such as rivastigmine exert their clinical effects. Copyright © 2010 John Wiley & Sons, Ltd.
- 15 March 2011
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 26 (4) , 356-363
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses
Objective In Alzheimer's disease (AD), rivastigmine has demonstrated statistically significant efficacy versus placebo on cognition and activities of daily living (ADL). The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items. Methods This exploratory analysis focused on the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS‐ADL) outcome from a large, international, 24‐week, controlled trial of rivastigmine once‐daily transdermal patch and twice‐daily capsules in AD (CENA713D2320, NCT00099242). Percentages of patients “improving” or “not worsening” on individual ADL items were calculated and changes from baseline with rivastigmine versus placebo were evaluated. Results Patients received rivastigmine patch (9.5 mg/24 h; n = 247), capsule (12 mg/day; n = 254), and placebo (n = 281). Statistically significant changes from baseline in composite ADCS‐ADL scores in both rivastigmine treatment groups versus placebo (p < 0.05) had previously been reported. In this responder analysis of the subset of patients who showed baseline functional impairments on each item, statistically significant differences favoring rivastigmine were seen on the following functions: bathing, clearing dishes, obtaining a beverage, garbage disposal, traveling, shopping, writing, using household appliances, and talking about current events. A responder analysis of emergence of ADL impairment was not as sensitive to treatment effects. Conclusions These findings suggest that rivastigmine may benefit specific ADL, particularly in patients who are already exhibiting functional impairment. Further research is required to improve understanding of how drugs such as rivastigmine exert their clinical effects. Copyright © 2010 John Wiley & Sons, Ltd.